Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Large Drop in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant decline in short interest in February. As of February 27th, there was short interest totaling 4,485 shares, a decline of 19.7% from the February 12th total of 5,585 shares. Based on an average trading volume of 19,031 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are short sold. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 19,031 shares, the short-interest ratio is presently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC acquired a new position in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Price Performance

NYSEAMERICAN MTNB traded down $0.03 during trading hours on Monday, reaching $0.61. 23,668 shares of the stock traded hands, compared to its average volume of 15,523. The stock has a 50 day simple moving average of $0.63 and a two-hundred day simple moving average of $1.07. Matinas Biopharma has a 1 year low of $0.47 and a 1 year high of $3.09. The company has a market cap of $3.93 million, a price-to-earnings ratio of -0.18 and a beta of 1.31.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.